SMYD2介导STAT1甲基化通过阻断JAK-STAT1信号通路保护肝脏缺血再灌注损伤
本研究探讨SMYD2对STAT1的翻译后修饰在肝脏缺血再灌注损伤中的作用。研究发现SMYD2与STAT1相互作用并介导其K175位点甲基化,抑制STAT1磷酸化及核转位;SMYD2过表达减轻损伤,而基因缺失或药理抑制加重损伤。临床相关性显示SMYD2表达升高与肝切除术后肝功能改善及手术结局较好相关。
要点
- SMYD2通过甲基化STAT1 K175抑制JAK-STAT1信号通路,减轻肝脏缺血再灌注损伤。
- SMYD2过表达保护肝脏,基因缺失或药理抑制则加重缺血再灌注损伤。
- SMYD2表达升高与肝切除术后肝功能改善及较好手术结局相关。
核心结论
- SMYD2是STAT1活性的新型负调控因子,通过K175甲基化精细调控STAT1信号,靶向SMYD2-STAT1轴可能成为减轻肝脏缺血再灌注损伤的治疗策略。
研究设计与样本
- 采用整合转录组-蛋白质组方法及功能筛选鉴定SMYD2为肝脏缺血再灌注损伤中STAT1激活的关键调控因子。
- 通过体外和体内功能缺失与功能获得研究验证SMYD2的机制作用,并结合临床相关性分析SMYD2表达与术后肝功能的关系。
主要发现
- SMYD2通过JAK-STAT1通路调控肝脏缺血再灌注损伤。
- 临床上SMYD2表达升高与肝切除术后肝功能改善及较好手术结局相关。
- 机制上SMYD2与STAT1物理相互作用并介导其赖氨酸175(K175)位点甲基化,从而抑制STAT1磷酸化及核转位。
- 体外和体内研究显示SMYD2过表达减轻肝脏缺血再灌注损伤,而基因缺失或药理抑制加重损伤。
临床怎么用
- SMYD2表达水平可能作为肝切除术后肝功能及手术结局的潜在生物标志物。
- 靶向SMYD2-STAT1轴可能为减轻肝脏缺血再灌注损伤提供新的治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The JAK/STAT pathway plays a pivotal role in hepatic ischaemia/reperfusion (I/R) injury, a serious perioperative complication. Although signal transducers and activators of transcription 1 (STAT1) activation is known to drive I/R-induced injury, the specific post-translational modifications (PTMs) governing its activity in hepatic I/R remain poorly understood. OBJECTIVE: This study identifies SMYD2, SET and MYND domain Containing 2 (SMYD2) as a critical regulator of STAT1 and investigates the mechanistic basis of SMYD2-mediated PTMs in modulating STAT1 function during hepatic I/R. DESIGN: Using an integrated transcriptomic-proteomic approach and functional screening, we identified SMYD2 as a critical regulator of STAT1 activation in hepatic I/R injury. Clinical correlations linked SMYD2 expression to postoperative liver function, while loss-of-function and gain-of-function studies in vitro and in vivo validated its mechanistic role. RESULTS: Our findings demonstrate that SMYD2 modulates hepatic I/R injury through the JAK-STAT1 pathway. Clinically, elevated SMYD2 expression correlated with improved liver function and better surgical outcomes following hepatectomy. Mechanistic studies revealed that SMYD2 physically interacts with STAT1 and mediates its methylation at lysine 175 (K175), thereby inhibiting STAT1 phosphorylation and nuclear translocation. Both in vitro and in vivo studies demonstrated that SMYD2 overexpression alleviated hepatic I/R injury, whereas its genetic depletion or pharmacological inhibition exacerbated the damage. CONCLUSION: This study establishes SMYD2 as a novel negative regulator of STAT1 activity through K175 methylation, providing new insights into the epigenetic control of STAT1 during hepatic I/R injury. Our findings reveal a previously unrecognised mechanism for fine-tuning STAT1 signalling in hepatic I/R injury, and targeting the SMYD2-STAT1 axis may present a promising therapeutic strategy for mitigating I/R-associated liver damage.
引用
- Yang Z, Hu Y, Yang C, et al. SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways. Gut. 2026. PMID: 41107038. doi:10.1136/gutjnl-2025-336400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。